Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
A phase 1/2 trial of TC011 in diffuse large b-cell lymphoma and follicular lymphoma, run by TICAROS Co., Ltd., now recruiting.
Overview
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients is a phase 1/2 interventional study registered as NCT07473167 by TICAROS Co., Ltd., with 98 participants planned, started 2023-08-03 and due to reach its primary completion in 2028-02-11. Interventions recorded: TC011. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL). No results are recorded here; the registry entry is the source.
Setting
A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Phase
Phase 1/2
Sponsor
TICAROS Co., Ltd.
Registry
Enrolled
98
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
- CompanyBiogen
- PersonFranck Morschhauser
- JournalHematological oncology
- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
- PersonYuqin Song
- TrialA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr
- TrialA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies